A Winship research team, led by Eric Miller (PhCB), has been named the inaugural recipient of a Winship Catalyst Fund award for their project, “Best-in-class orally bioavailable small molecule CXCR4 antagonists for cancer treatment.” Provided through a generous philanthropic gift from Berry Gray, the Winship Catalyst Fund supports the development of novel approaches for cancer therapy, diagnostics, or prevention, with the goal of seeking an investigational new drug (IND) application from the FDA.